ClinicalTrials.gg
Not yet recruitingNCT07860879Updated Oct 6, 2026

Weaning Assessment by Peripheral Muscle Ultrasonography

An observational study in ICU Stay, Muscle Atrophy and Ultrasonography, sponsored by Taksim Egitim ve Arastirma Hastanesi. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Taksim Egitim ve Arastirma Hastanesi · Observational

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

In this study, which aims to investigate the relationship between the weaning process and respiratory muscles-assessed via ultrasonographic measurement of peripheral muscle thickness-in patients over the age of 18 who have been in the intensive care unit for more than 24 hours, we will also examine whether there is a significant correlation between peripheral muscle thickness and diaphragm thickness, whether ultrasonographic findings correlate with weaning parameters, and whether peripheral muscle atrophy and diaphragm involvement are parallel or distinct processes.

Read the detailed description

Sarcopenia and muscle atrophy are commonly observed during prolonged stays in the intensive care unit (ICU). This condition is not limited to the extremities but affects all systems containing muscle tissue. Respiratory effort and the function of respiratory muscles are crucial factors during the process of weaning intubated ICU patients from mechanical ventilation. It is known that muscle loss in the ICU is a complex process associated with the severity of critical illness and mechanical ventilation, rather than resulting solely from immobilization; however, there are limited studies examining the relationship between peripheral muscle and the diaphragm in conjunction with weaning parameters. The data obtained from this study could contribute to predicting the weaning process and shaping early rehabilitation strategies in the ICU. The primary objective of this study is to evaluate the relationship between peripheral muscle thickness and diaphragm thickness-measured via ultrasonography-in patients over the age of 18 who have been in the ICU for more than 24 hours. Additionally, the study aims to investigate the impact of changes in muscle thickness on the weaning process and the ICU course, as well as to examine their associations with weaning parameters.

In the study, the following data will be recorded for patients who have stayed in the intensive care unit (ICU) for more than 24 hours: age, gender, height, weight, BMI, ICU admission diagnosis, APACHE II and SOFA scores, presence of culture-confirmed sepsis, total duration of mechanical ventilation, duration of sedation (using the Ramsay Sedation Scale), sedatives/neuromuscular blockers/corticosteroids used, nutritional method and daily protein intake, and laboratory data (albumin, CK, CRP).

Peripheral muscle measurements will be performed via ultrasonography by measuring rectus femoris or vastus intermedius thickness; the total quadriceps muscle thickness may also be recorded as data if desired.

Diaphragm measurements will be based on diaphragm thickness, diaphragm thickening fraction, and-where possible-diaphragm excursion.

Parameters to be recorded regarding weaning include: RSBI, spontaneous breathing trial outcome, MIP/NIF, tidal volume, respiratory rate, P0.1 (if available), extubation success or failure, occurrence of re-extubation within 48 hours, and the need for tracheostomy.

02

Conditions studied

  • ICU Stay
  • Muscle Atrophy
  • Ultrasonography
  • Weaning Mechanical Ventilation

Browse trials for

Keywords

  • muscla ultrasonography
  • muscle atrophy
03

In context

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

This study's planned enrollment of 100 is above the median of 61 across 73 observational studies indexed under Muscular Atrophy.

Browse Muscular Atrophy studies →

Lead sponsor

Taksim Egitim ve Arastirma Hastanesi is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient group aged 18 and older with an intensive care stay exceeding 24 hours.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 18 years of age or older.
  • Having been in the intensive care unit for more than 24 hours.
  • Having no to undergoing an ultrasonographic assessment.

Exclusion criteria

Exclusion Criteria:

  • Known neuromuscular disease.
  • Significant motor paralysis due to cervical spinal cord injury or advanced central nervous system lesion.
  • Advanced-stage primary muscle disease directly affecting muscle mass.
  • Thoracic wall deformity or a condition technically preventing assessment of the diaphragm.
  • Amputation, severe peripheral trauma, or local pathology in the muscle to be measured.
  • Pregnancy.
  • Inability to obtain consent from a legal representative for participation in the study.
  • Patients with a very short , where it is anticipated that the data collection protocol cannot be completed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Interventions

  • Diagnostic testUltrasonography of peripheral muscle (rectus femoris or vastus intermedius)

    The measurement of peripheral muscle thickness by ultrasonography. Rectus femoris or vastus intermedius will be measured (Or the total of quadriceps).

  • Diagnostic testUltrasonography of diaphragma

    Diaphragm thickness, diaphragm thickening fraction, and, if possible, diaphragm excursion will be measured.

06

What researchers measure

Primary outcomes

  1. Correlation Coefficient Between Total Quadriceps Muscle Thickness and End-Expiratory Diaphragm Thickness Measured by Ultrasonography

    Total quadriceps muscle thickness will be calculated as the sum of rectus femoris and vastus intermedius muscle thicknesses, measured in millimeters using bedside ultrasonography. End-expiratory diaphragm thickness will be measured in millimeters using bedside ultrasonography at the same assessment. The outcome will be the Pearson or Spearman correlation coefficient between these two measurements across participants, according to the data distribution. The coefficient is dimensionless and ranges from -1 to +1. A separate coefficient will be reported for each scheduled assessment time point. Baseline assessment will include participants regardless of intubation status. Subsequent assessments will apply to participants who are intubated and those undergoing planned extubation, respectively.

    Time frame: At ICU admission (baseline); 24-48 hours after intubation; and immediately before planned extubation.

Secondary outcomes

  1. Correlation Coefficient Between Total Quadriceps Muscle Thickness and Diaphragm Thickening Fraction Measured by Ultrasonography

    Total quadriceps muscle thickness will be calculated as the sum of rectus femoris and vastus intermedius muscle thicknesses, measured in millimeters using bedside ultrasonography. Diaphragm thickening fraction will be calculated from ultrasound measurements as: \[(end-inspiratory diaphragm thickness - end-expiratory diaphragm thickness) / end-expiratory diaphragm thickness\] × 100, and expressed as a percentage. The outcome will be the Pearson or Spearman correlation coefficient between total quadriceps muscle thickness and diaphragm thickening fraction across participants, according to the data distribution. The coefficient is dimensionless and ranges from -1 to +1. A separate coefficient will be reported for each scheduled assessment time point. Baseline assessment will include participants regardless of intubation status. Subsequent assessments will apply to participants who are intubated and those undergoing planned extubation, respectively.

    Time frame: At ICU admission (baseline); 24-48 hours after intubation; and immediately before planned extubation.

  2. Mean Percentage Change From Baseline in Total Quadriceps Muscle Thickness Measured by Ultrasonography

    Total quadriceps muscle thickness will be calculated as the sum of rectus femoris and vastus intermedius muscle thicknesses, measured in millimeters using bedside ultrasonography. For each participant, percentage change from the ICU admission measurement will be calculated as: \[(follow-up thickness - baseline thickness) / baseline thickness\] × 100. Negative values indicate a reduction in muscle thickness. The mean of the participant-level percentage changes will be reported separately for each follow-up time point using participants with paired baseline and follow-up measurements. The outcome unit is percent (%).

    Time frame: From ICU admission (baseline) to 24-48 hours after intubation; and from ICU admission (baseline) to immediately before planned extubation.

  3. Mean Percentage Change From Baseline in End-Expiratory Diaphragm Thickness Measured by Ultrasonography

    End-expiratory diaphragm thickness will be measured in millimeters using bedside ultrasonography. For each participant, percentage change from the ICU admission measurement will be calculated as: \[(follow-up thickness - baseline thickness) / baseline thickness\] × 100. Negative values indicate a reduction in diaphragm thickness. The mean of the participant-level percentage changes will be reported separately for each follow-up time point using participants with paired baseline and follow-up measurements. The outcome unit is percent (%).

    Time frame: From ICU admission (baseline) to 24-48 hours after intubation; and from ICU admission (baseline) to immediately before planned extubation.

  4. Percentage of Participants With Successful Extubation at 48 Hours

    Successful extubation will be defined as remaining alive and free from invasive mechanical ventilation throughout the first 48 hours following the first planned extubation during the ICU stay. Extubation outcome will be determined from clinical follow-up and medical records. The percentage will be calculated as the number of participants meeting the success definition divided by the number of participants undergoing the first planned extubation, multiplied by 100. Noninvasive respiratory support alone will not constitute failure under this definition.

    Time frame: From the first planned extubation through 48 hours after extubation.

  5. Percentage of Participants Requiring Reintubation Within 48 Hours After Planned Extubation

    Reintubation will be defined as reinsertion of an endotracheal tube within 48 hours after the first planned extubation during the ICU stay, as documented in medical records. The percentage will be calculated as the number of participants requiring reintubation within 48 hours divided by the number of participants undergoing the first planned extubation, multiplied by 100.

    Time frame: From the first planned extubation through 48 hours after extubation.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

Of 36 non-industry observational studies under Muscular Atrophy, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 66. This study's planned 11 months is below that.

Counting every sponsor, half of 38 studies reached it within 35 months; a quarter within 18 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Oct 6, 2026
StartEst.
Sep 25, 2026
Primary completionEst.
Aug 25, 2027
CompletionEst.
Sep 25, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860879
Lead sponsor
Taksim Egitim ve Arastirma Hastanesi
Responsible party
Canberk Çetinel (Assistant researcher, Taksim Egitim ve Arastirma Hastanesi) — Principal investigator
First posted
Oct 6, 2026
Start date
Sep 25, 2026 (estimated)
Primary completion
Aug 25, 2027 (estimated)
Completion
Sep 25, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Yasemin Tekdöş Şeker Associate Professor, MD
Contact
yasemintekdos@gmail.com
+90 532 475 51 54

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion